This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (48) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hayman, R. Articles by Baker, P. Search for Related Content PubMed PubMed Citation Articles by Hayman, R. Articles by Brockelsby, J. Articles by Kenny, L. Articles by Baker, P. Social Bookmarking                         What's this?

Preeclampsia: The Endothelium, Circulating Factor(s) and Vascular Endothelial Growth Factor

Jeremy Brockelsby, MB, BS

Louise Kenny, MB, ChB

Department of Human Development, City Hospital, University of Nottingham, Nottingham, United Kingdom

Philip Baker, DM

Department of Human Development, City Hospital, University of Nottingham, Nottingham, United Kingdom; Department of Obstetrics & Gynecology, City Hospital, University of Nottingham, Hucknall Road, Nottingham, NG5 1PB, United Kingdom philip.baker{at}nottingham.ac.uk

It has been proosed that endothelial cell activation is the primary event in the multisystem disorder of preeclampsia. Evidence for endothelial involvement in this condition abounds. The best-characterized morphologic abnonnality of this syndrome, glomerular endotheliosis, involves endothelial cells. Also associated with preeclampsia is a loss of endothelial cell integrity, with the consequent increase in vascular penneability, and an increase in the circulating levels of the endothelial cell markers, fibronection, von Willebrand factor, tissue plasminogen activator, and plasminogen activator inhibitor-1. It is now well documented that endothelial activation contributes to the coagulation abnormalities observed in this disease. There is much evidence that the endothelial alteractions in preeclampsia results from one or more circulating factors. The incubation of cultured endothelial cells with serum or plasma samples, taken from normal pregnant women and women with preeclampsia, results in marked alterations in cell behavior and metabolic processes. More recently, experiments employing myographic techniques have demonstrated convincingly the effects of a circulating factor(s) on the function of endothelial cells of resistance arteries. Vascular endothelial growth factor (VEGF) possesses many of the characteristics required of a candidate circulating factor. It contains a hydrophobic secretory signal sequence, exerts in vitro effects specific to vascular endothelial cell, and promotes endothelial expression of procoagulant activity. Circulating VEGF concentrations are elevated in women with preeclampsia, and VEGF increases microvascular endothelial cell prostacyclin production in a dose-dependent manner, analogous to the acute effects of plasma from patients with preeclampsia. Similarly, in myographic studies, when myometrial resistance arteries are incubated with VEGF, there are dose-dependent alterations in endothelium-dependent behavior, mirrorng those found after incubation with plasma from patients with preeclampsia.

Key Words: Preeclampsia • endothelium • circulating factor • vascular endothelial growth factor • myography

Journal of the Society for Gynecologic Investigation, Vol. 6, No. 1, 3-10 (1999)
DOI: 10.1177/107155769900600103


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?